Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis
Acta Dermato-Venereologica · 2023
DOI: 10.2340/actadv.v103.12445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Dermato-Venereologica, 2023. Verfasst von Nicolae Done und 6 weiteren Autor:innen. Beteiligte Einrichtung: Analysis Group, Boston, MA, US. Nicolae.Done@analysisgroup.com. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Alopecia areata is an autoimmune disorder characterized by hair loss, for which there are few treatment options. This claims-based study characterized recent real-world treatment patterns among patients in the USA with alopecia areata, including the subtypes alopecia totalis and alopecia universalis, in the first year after diagnosis of an episode of alopecia areata. Approximately 5% of all patients (adults (age ≥ 18 years), n = 7,703; adolescents (age 12–17 years), n = 595) had alopecia totalis or alopecia universalis. Corticosteroids were the most common first-line (1L) and second-line (2L) treatments. The mean time from diagnosis of alopecia areata to initiation of 1L treatment was 2.2 days for adults and 2.6 days for adolescents; mean 1L duration was 76.9 and 64.3 days, respectively. For adults (57.5%) and adolescents (59.7%) with 2L therapy, the mean time from 1L discontinuation to 2L initiation was 57.2 and 53.6 days, respectively; the mean duration of 2L treatment was 55.5 and 50.1 days, respectively. More patients with vs without alopecia totalis or alopecia universalis initiated 2L therapy (adults: 71.9% vs 56.8%; adolescents: 71.4% vs 58.9%). The proportion of days covered during the first year post-diagnosis was 36.7% (adults) and 34.1% (adolescents). These results highlight the substantial disease burden of alopecia areata and a need for more effective treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Analysis Group, Boston, MA, US. Nicolae.Done@analysisgroup.com.
- Pfizer, Collegeville, PA, USA.
- Analysis Group, Boston, MA, US.
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Förderung
- Pfizer
Zitieren
APA
Done, N., Bartolome, L., Swallow, E., Gao, W., Carley, C., Wang, T., & Mostaghimi, A. (2023). Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v103.12445
Vancouver
Done N, Bartolome L, Swallow E, Gao W, Carley C, Wang T, et al. Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis. Acta Dermato-Venereologica. 2023. doi:10.2340/actadv.v103.12445
BibTeX
@article{Done2023,
author = {Done, Nicolae and Bartolome, Lauren and Swallow, Elyse and Gao, Wei and Carley, Christopher and Wang, Travis and Mostaghimi, Arash},
title = {Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis},
journal = {Acta Dermato-Venereologica},
year = {2023},
doi = {10.2340/actadv.v103.12445}
}
EUVIMED